BIOVIE INC.
BIVINasdaq
$1.80
↑ +4.7%Jul 17 close · end-of-day
Price
1Y↓ -75.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$13.6M
Enterprise Value
$480,085.40
P/E
—
P/S
—
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$19.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-127.6%
ROIC
-648.6%
Debt / Equity
—
Net Cash
$13.1M
Return 1Y
-77.6%
Company profile
BioVie Inc. engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trials for Alzheimer's, Parkinson's and multiple myeloma and prostate cancer.
- CEO
- Cuong V. Do
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Nevada
- Website
- bioviepharma.com
Earnings
BIVI Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.70↓ -53.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$138.1M | -$27.3M | -$45.1M | -$32.2M | -$18.1M |
| Net income | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M |
| Diluted EPS | -$14.82 | -$1.06 | -$15.47 | -$73.05 | -$12.12 |
| Operating cash flow | -$10.5M | -$19.0M | -$40.3M | -$27.9M | -$19.0M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.8M | -$4.1M | -$7.3M | -$3.0M | -$3.7M | -$5.3M | -$6.3M | -$5.4M |
| Net income | -$4.9M | -$4.2M | -$7.1M | -$2.8M | -$3.5M | -$5.1M | -$6.1M | -$5.3M |
| Diluted EPS | -$65.93 | -$7.00 | -$4.55 | -$1.51 | $0.94 | -$0.98 | -$0.77 | -$0.70 |
| Operating cash flow | -$4.0M | -$3.6M | -$8.6M | -$1.3M | -$5.6M | -$3.0M | -$4.4M | -$7.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 29, 2026
May 27, 2026
May 26, 2026
- 55d agoBioVie completes enrollment in Long COVID trial as need for treatments growsfinance.yahoo.com
- 55d agoBioVie completes enrollment in Phase 2 Long COVID trialproactiveinvestors.com
- 55d agoBioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDfinance.yahoo.com
May 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-07 | Do Cuong V· President & CEO | Buy | 5,000 | — | — | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.